menu

Medical Industry Feature: The BiTE® Immuno-Oncology Platform & Emerging Targets in Oncology

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Menopause

The BiTE® Immuno-Oncology Platform & Emerging Targets in Oncology

Program Information
Recommended
The BiTE® Immuno-Oncology Platform & Emerging Targets in Oncology
RestartResume
Learn how a immuno-oncology platform designed to lead to off-the-shelf therapies could change our approach to fight cancer.
  • Sponsored by

  • Overview

    Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Binrholz is joined by Dr. Ajai Chari.

                                                                                                                                         USA-OCF-80679

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/13/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.